Ifinatamab Deruxtecan Continues to Display Promising Goal Response Charges in Sufferers with Intensive-Stage Small Cell Lung Most cancers in IDeate-Lung01 Part 2 Trial By Investing.com
Goal response price of 54.8% seen with Daiichi Sankyo and Merck's ifinatamab…
